NICE

News

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

NICE backs NHS use of Roche's Columvi as a second-line therapy for a form of non-Hodgkin lymphoma affecting thousands of people in the UK each year.

News

"Significant shift" as NICE widens prostate cancer drug use

NICE has changed unpopular guidance on abiraterone for hormone-sensitive prostate cancer after the entry of generics into the UK market.

News

A male HCP discusses treatment with an older male patient

Bayer's prostate cancer drug Nubeqa cleared for NHS use

Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

News

Pharmacist shelving medicine in pharmacy

NHS could pay more for medicines under new plan

Changes to the threshold used by NICE to measure cost-effectiveness could be on the way as part of a plan that would raise NHS spending on medicines.

News

BMS says it will set Cobenfy's UK price the same as the US

Bristol Myers Squibb's price tag for schizophrenia drug Cobenfy in the UK is a manifestation of Trump's most favoured nation drug pricing policy.

News

Imfinzi becomes first NHS drug for aggressive lung cancer

AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

"Significant shift" as NICE widens prostate cancer drug use

Bayer's prostate cancer drug Nubeqa cleared for NHS use

NHS could pay more for medicines under new plan

BMS says it will set Cobenfy's UK price the same as the US

Imfinzi becomes first NHS drug for aggressive lung cancer

Trump sets course for 100%, then 200%, tariffs on generics

Discover a new era of healthcare panel engagement: Grounded ...

NICE

Editor's Picks